Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026
Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026
Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026
Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026
Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026
Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026
Company Deals

Joincare Pharmaceutical Plans to Acquire 64.81% Stake in Imexpharm for USD 220M

Fineline Cube May 23, 2025

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to acquire a 64.81%...

Company Drug

Chongqing Genrix Bio’s GR2001 Tetanus Monoclonal Antibody NDA Accepted by NMPA

Fineline Cube May 23, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) recently announced that its New Drug...

Company Medical Device

Medtronic Plans to Spin Off Diabetes Business into Publicly Traded Entity

Fineline Cube May 23, 2025

Medtronic plc (NYSE: MDT), the US-headquartered medical technology company, has unveiled plans to spin off...

Company Drug

Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation

Fineline Cube May 23, 2025

German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for...

Company Drug

InnoCare Pharma’s Minjuvi Gains NMPA Approval for DLBCL Treatment

Fineline Cube May 23, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the National Medical Products Administration (NMPA)...

Company Drug

Uni-Bio Science’s Generic Diquas Accepted for NMPA Review

Fineline Cube May 23, 2025

China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...

Company Drug

MicusRx’s Contezolid Sodium NDA Accepted for Review by NMPA

Fineline Cube May 23, 2025

China-based Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) announced that a New Drug Application (NDA)...

Company Deals

Sanofi to Acquire Vigil Neuroscience to Boost Neurology Pipeline

Fineline Cube May 23, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) is set to acquire US-based Vigil Neuroscience, Inc., a...

Company Drug

Eli Lilly’s Kisunla Approved in Australia for Alzheimer’s Treatment

Fineline Cube May 23, 2025

The Australian Therapeutic Goods Administration (TGA) this week approved Eli Lilly and Company’s (NYSE: LLY)...

Company Deals

Shanghai INT Medical Instruments to Acquire Majority Stake in Endonom Medical

Fineline Cube May 22, 2025

China-based Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501) is set to jointly acquire a...

Company

Medtronic Reports Q4 and FY2025 Results with Revenue Growth Across Key Segments

Fineline Cube May 22, 2025

US-Irish firm Medtronic (NYSE: MDT) released financial results for its fourth quarter (Q4) and fiscal...

Company Deals

Genentech and Orionis Enter Second Collaboration on Small-Molecule Oncology Drugs

Fineline Cube May 22, 2025

Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY), this week entered...

Company Drug

Kexing Biopharm’s GB18 Receives FDA Approval for Tumor Cachexia Clinical Trial

Fineline Cube May 22, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced receiving clinical trial approval from the US...

Company Drug

Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment

Fineline Cube May 22, 2025

Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...

Company Drug

Simcere’s FGFR2b-Targeting ADC SIM0686 Enters Phase I Clinical Study

Fineline Cube May 22, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study...

Company Drug

Triastek’s T22 Gastric Retention Capsules Gain NMPA IND Clearance

Fineline Cube May 22, 2025

Nanjing-based Triastek Inc., a pioneer in 3D-printed pharmaceutical formulations, has obtained Investigational New Drug (IND)...

Company Drug

Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke

Fineline Cube May 22, 2025

Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...

Company

Well Lead Medical to Set Up Subsidiary and Manufacturing Base in Indonesia

Fineline Cube May 22, 2025

Guangzhou-based medical catheter specialist Well Lead Medical Co., Ltd (SHA: 603309) plans to establish a...

Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer

Fineline Cube May 22, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...

Company Deals

Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D

Fineline Cube May 22, 2025

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted...

Posts pagination

1 … 111 112 113 … 619

Recent updates

  • Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
  • Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
  • Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial
  • Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa
  • Marubeni Launches Xenleta in China After Complex Licensing Journey
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.